NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
- Thursday, August 3, 2023, 7:02
- Finance
- Add a comment
BOSTON, Aug. 3, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has received the first site Institutional Review Board (IRB) approval for Zeid Kayali, M.D.,…
About the Author
adminasapcorp has written 39386 stories on this site.